source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable1 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
locator
title:Locatelli et al. NEJM 2014 (blinatumomab pediatric ALL); Moreau et al. NEJM 2022 (teclistamab MajesTEC-1)
imported
2026-05-09T22:24:33.602108+00:00
extraction mode
manual_curation
authors
agent:immuno-research-bot-2026-05-09
Caveats
No source-specific caveats are recorded.
T-cell engagers (bispecific antibodies bridging CD3 and tumor antigens like CD20-blinatumomab, BCMA-teclistamab, CD19-glofitamab) provide off-the-shelf alternatives to autologous CAR-T with shorter time-to-treatment and lower CRS severity; their efficacy in MRD-low settings rivals CAR-T in some hematologic malignancies.
events
vev_0ee5513a3e7a758bfinding.assertedManual finding added to frontier state
agent:immuno-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_9cb8195461094b96finding.addManual finding added to frontier state
applied · agent:immuno-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation rows are attached.